UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
(Amendment No.1)
Under the Securities Exchange Act of 1934
Keryx Biopharmaceuticals, Inc.
------------------------------
Common Stock, no par value per share
------------------------------------
(Title of Class of Securities)
492515101
------------
CUSIP Number
December 31, 2003
------------------------------------
(Date of Event which Requires Filing
of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[X] Rule 13d-1(c)
[ ] Rule 13d-1(d)
*The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required on the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act (however, see the
Notes).
Continued on following pages
Page 1 of 5 Pages
SCHEDULE 13G
CUSIP No. 492505101 Page 2 of 5
1 Names of Reporting Persons
I.R.S. Identification Nos. of above persons (entities only)
JAY LOBELL
2 Check the Appropriate Box If a Member of a Group *
a. [ ]
b. [X]
3 SEC Use Only
4 Citizenship or Place of Organization
UNITED STATES
5 Sole Voting Power
Number of 2,374,187
Shares
Beneficially 6 Shared Voting Power
Owned By 0
Each
Reporting 7 Sole Dispositive Power
Person 2,374,187
With
8 Shared Dispositive Power
0
9 Aggregate Amount Beneficially Owned by Each Reporting Person
2,374,187
10 Check Box If the Aggregate Amount in Row (9) Excludes Certain
Shares *
[ ]
11 Percent of Class Represented By Amount in Row (9)
11.68%
12 Type of Reporting Person *
IN
* see instructions before filling out
CUSIP No. 492505101 Page 3 of 5
Item 1(a) Name of Issuer:
Keryx Biopharmaceuticals Inc.. (the "Issuer")
Item 1(b) Address of the Issuer's Principal Executive Offices:
750 LEXINGTON AVENUE
NEW YORK, NY 10022
BUSINESS PHONE: 212-531-5965
Item 2(a) Name of Person Filing:
Jay Lobell (the "Reporting Person").
Item 2(b) Address of Principal Business Office or, if None, Residence:
365 West End Ave. NY, NY 10024
Item 2(c) Citizenship:
Mr. Lobell is a citizen of the United States.
Item 2(d) Title of Class of Securities:
Common Stock (the "Shares").
Item 2(e) CUSIP Number:
492505101
Item 3. If this statement is filed pursuant to Rule 13d-1(b), or
13d-2(b) or (c), check whether the person filing is a:
This Item 3 is not applicable.
Item 4. Ownership:
Item 4(a) Amount Beneficially Owned:
Each of the Reporting Persons may be deemed the beneficial
owner of the following number of Shares:
Mr. Lobell may be deemed the beneficial owner of 2,374,187
Shares. Beneficial ownership consists of voting and
dispositive power over (i) 1,000,000 Shares owned by the
Rosenwald 2000 Family Trust, for which Mr. Lobell serves as
the trustee and (ii) 1,374,187 shares owned by the Lindsay A.
Rosenwald 2000 (Delaware) Irrevocable Indenture of Trust for
which Mr. Lobell is investment manager.
Item 4(b) Percent of Class:
Please see Item 11 of each cover page.
CUSIP No. 492505101 Page 4 of 5
Item 4(c) Number of shares as to which such person has:
(i) Sole power to vote or Please see Item 5 of each
direct the vote: cover page
(ii) Shared power to vote or Please see Item 6 of each
to direct the vote cover page
(iii) Sole power to dispose or to Please see Item 7 of each
direct the disposition of cover page
(iv) Shared power to dispose or Please see Item 8 of each
to direct the disposition of cover page
Item 5. Ownership of Five Percent or Less of a Class:
This Item 5 is not applicable.
Item 6. Ownership of More than Five Percent on Behalf of Another
Person:
See Item 4 Above
Item 7. Identification and Classification of the Subsidiary Which
Acquired the Security Being Reported on by the Parent Holding
Company:
This Item 7 is not applicable.
Item 8. Identification and Classification of Members of the Group:
This Item 8 is not applicable.
Item 9. Notice of Dissolution of Group:
This Item 9 is not applicable.
Item 10. Certification:
By signing below each of the Reporting Persons certifies that,
to the best of such person's knowledge and belief, the securities referred to
above were not acquired and are not held for the purpose of or with the effect
of changing or influencing the control of the Issuer of the securities and were
not acquired and are not held in connection with or as a participant in any
transaction having such purpose or effect.
Page 5 of 5
SIGNATURES
After reasonable inquiry and to the best of my knowledge and belief,
the undersigned certifies that the information set forth in this statement is
true, complete and correct, as of this February 2, 2004.
JAY LOBELL
By /s/ Jay Lobell
--------------------------